Skip to main
HAE
HAE logo

Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics (HAE) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 53%
Buy 18%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Haemonetics Corp has demonstrated strong financial performance, with its gross margin increasing by 240 basis points year-over-year and its operating margin rising by 390 basis points year-over-year, contributing to a projected FY25 operating margin of approximately 24%. The company's plasma revenue experienced growth attributed to premium pricing from technology upgrades, alongside share gains and increased collections, while the hospital segment, particularly the vascular closure business, also reported impressive growth rates in the mid-20s percentage range. Potential growth drivers include an acceleration in plasma collection volumes, further margin enhancements, and strategic acquisitions, reinforcing a positive outlook for its financial trajectory.

Bears say

Haemonetics Corp has experienced a substantial slowdown in its revenue growth, with overall organic revenue declining to -0.3% in F3Q25, down from 3.7% in F2Q25, indicating potential operational challenges. The company has revised its growth expectations downward, particularly for the plasma and hospital segments, projecting organic growth rates of 12-14% for the hospital segment and a decline of 5-7% for the blood center segment in FY25. Furthermore, the bear case scenario suggests that revenue could slow to low-single digits, exacerbating concerns regarding operating margins and earnings that fall below consensus estimates, thus contributing to a negative outlook on the stock.

Haemonetics (HAE) has been analyzed by 17 analysts, with a consensus rating of Buy. 53% of analysts recommend a Strong Buy, 18% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Haemonetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Haemonetics (HAE) Forecast

Analysts have given Haemonetics (HAE) a Buy based on their latest research and market trends.

According to 17 analysts, Haemonetics (HAE) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $83.18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $83.18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Haemonetics (HAE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.